FDA's 510(k) Action Plan Draws Praise, Criticism from Proteomics Diagnostics Community | GenomeWeb

By Adam Bonislawski

Two weeks after the US Food and Drug Administration released its 25-point action plan for revamping the 510(k) submission process, response from the proteomics-based diagnostics community has ranged from polite applause to a stifled yawn to open disappointment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.